P37.04 EGFR Mutations in US Hispanics with Lung Adenocarcinoma are Common and Portend a Worse Prognosis
نویسندگان
چکیده
Activating mutations in Epidermal growth factor receptor (EGFR) occur approximately 15% White, 40-50% of Asian and Black patients with lung adenocarcinoma. However, its prevalence the nearly 60 million U.S. Hispanics has not been well characterized. Herein we evaluate EGFR mutation frequency Hispanic adenocarcinoma at an academic institute serving a large multi-ethnic area.
منابع مشابه
The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
This study aimed to elucidate the association of the content of mutant epidermal growth factor receptor (EGFR) deoxyribonucleic acid (DNA) with the treatment response to EGFR-tyrosine kinase inhibitor (TKI) and survival in patients with lung cancer.This retrospective cohort study included 77 lung adenocarcinoma patients with common EGFR mutations from December 2012 to February 2015. The content...
متن کاملEGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma
In this study, EGFR-activating mutation status and DNA copy number abundances of members of ErbB family were measured in 261 lung adenocarcinomas. The associations between DNA copy number abundances of ErbB family, EGFR-activating mutation status, and prognosis were explored. Results showed that DNA copy number abundances of EGFR, ERBB2, ERBB3, and ERBB4 had associations with overall survival i...
متن کاملKRAS and EGFR mutations coexisting in lung adenocarcinoma
Lung adenocarcinoma represents about 42% and 28% of NSCLC in women and men. Adenocarcinomas incidence is still rising being the most frequent type of NSCLC diagnosed in USA. Both EGFR and KRAS gene mutations can contribute to the development of NSCLC, namely adenocarcinomas. EGFR and KRAS mutations are considered by some authors as mutually exclusive explained by the fact that KRAS-MAPK pathway...
متن کاملCurrent two EGFR mutations in lung adenocarcinoma - case report.
Nowadays, EGFR TKIs (epidermal growth factor receptor-tyrosine kinase inhibitors) targeted therapy is well established treatment for patients with the so-called EGFR common mutations with advanced or metastatic nonsmall cell lung cancer. The efficacy for the so-called rare and especially for the very rare complex EGFR mutations is not clear. We describe a case of a 63- year-old female with meta...
متن کاملFrequent EGFR mutations in malignant pleural effusion of lung adenocarcinoma
Frequent EGFR mutations in malignant pleural effusion of lung adenocarcinoma Shang-Gin Wu, Chien-Hung Gow, Chong-Jen Yu, Yih-Leong Chang, Chih-Hsin Yang, Ya-chieh Hsu, Jin-Yuan Shih*, Yung-Chie Lee, Pan-Chyr Yang 1 Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. 2 Division of Critical Care Medicine, Department of Emergency and Critical Care Medicine, Lotung...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2021
ISSN: ['1556-0864', '1556-1380']
DOI: https://doi.org/10.1016/j.jtho.2021.01.751